Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anus Neoplasms | 8 | 2020 | 330 | 3.320 |
Why?
|
Pancreatic Neoplasms | 41 | 2024 | 5366 | 3.140 |
Why?
|
Rectal Neoplasms | 22 | 2024 | 1156 | 3.110 |
Why?
|
Bile Duct Neoplasms | 11 | 2024 | 607 | 2.830 |
Why?
|
Cholangiocarcinoma | 12 | 2024 | 554 | 2.590 |
Why?
|
Neoadjuvant Therapy | 39 | 2024 | 2827 | 2.540 |
Why?
|
Liver Neoplasms | 21 | 2024 | 4309 | 2.010 |
Why?
|
Biliary Tract Neoplasms | 3 | 2020 | 185 | 1.850 |
Why?
|
Carcinoma, Hepatocellular | 15 | 2024 | 2293 | 1.780 |
Why?
|
Fluorouracil | 24 | 2023 | 1642 | 1.640 |
Why?
|
Radiosurgery | 10 | 2024 | 1339 | 1.610 |
Why?
|
Adenocarcinoma | 22 | 2023 | 6341 | 1.580 |
Why?
|
Lymphopenia | 3 | 2024 | 282 | 1.560 |
Why?
|
Stomach Neoplasms | 10 | 2024 | 1457 | 1.520 |
Why?
|
Carcinoma, Pancreatic Ductal | 16 | 2023 | 1726 | 1.480 |
Why?
|
Esophagogastric Junction | 3 | 2024 | 347 | 1.300 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 11733 | 1.080 |
Why?
|
Neoplasm Staging | 28 | 2024 | 11119 | 1.040 |
Why?
|
Gastrointestinal Neoplasms | 7 | 2021 | 955 | 1.000 |
Why?
|
Radiation Injuries | 6 | 2020 | 1191 | 0.960 |
Why?
|
Radiotherapy | 8 | 2021 | 1499 | 0.940 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2022 | 9278 | 0.880 |
Why?
|
Radiation Oncology | 6 | 2022 | 563 | 0.860 |
Why?
|
Esophageal Neoplasms | 6 | 2021 | 1658 | 0.850 |
Why?
|
Pelvis | 3 | 2020 | 735 | 0.790 |
Why?
|
Leucovorin | 13 | 2023 | 643 | 0.770 |
Why?
|
Fund Raising | 1 | 2021 | 49 | 0.760 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2021 | 128 | 0.720 |
Why?
|
Radiodermatitis | 1 | 2019 | 60 | 0.650 |
Why?
|
Radiotherapy Dosage | 16 | 2023 | 2897 | 0.650 |
Why?
|
Survival Rate | 23 | 2024 | 12728 | 0.640 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 116 | 0.600 |
Why?
|
Chemotherapy, Adjuvant | 11 | 2021 | 3512 | 0.600 |
Why?
|
Retrospective Studies | 58 | 2024 | 80674 | 0.580 |
Why?
|
Colonic Neoplasms | 4 | 2020 | 2527 | 0.570 |
Why?
|
Combined Modality Therapy | 15 | 2022 | 8519 | 0.560 |
Why?
|
Radiation Tolerance | 2 | 2019 | 478 | 0.560 |
Why?
|
Pelvic Bones | 2 | 2017 | 270 | 0.560 |
Why?
|
Preoperative Care | 3 | 2024 | 2241 | 0.550 |
Why?
|
Radiation Dosage | 4 | 2019 | 1962 | 0.520 |
Why?
|
Tumor Burden | 6 | 2021 | 1892 | 0.510 |
Why?
|
Humans | 154 | 2024 | 761208 | 0.510 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4021 | 0.510 |
Why?
|
Brachytherapy | 4 | 2022 | 1223 | 0.500 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2019 | 801 | 0.500 |
Why?
|
Aged | 75 | 2024 | 169288 | 0.500 |
Why?
|
Deoxycytidine | 6 | 2018 | 878 | 0.490 |
Why?
|
Lymphatic Metastasis | 8 | 2018 | 2913 | 0.490 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 233 | 0.490 |
Why?
|
Neutropenia | 2 | 2017 | 885 | 0.470 |
Why?
|
Photons | 2 | 2019 | 589 | 0.460 |
Why?
|
Middle Aged | 79 | 2024 | 220853 | 0.450 |
Why?
|
Community Health Centers | 1 | 2017 | 461 | 0.450 |
Why?
|
Kaplan-Meier Estimate | 9 | 2019 | 6486 | 0.450 |
Why?
|
Neoplasm Metastasis | 6 | 2020 | 4909 | 0.450 |
Why?
|
Aged, 80 and over | 35 | 2024 | 58952 | 0.430 |
Why?
|
Prognosis | 27 | 2024 | 29687 | 0.430 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2014 | 646 | 0.430 |
Why?
|
Anal Canal | 3 | 2020 | 374 | 0.410 |
Why?
|
Blood Vessels | 1 | 2018 | 1111 | 0.410 |
Why?
|
Mitomycin | 3 | 2019 | 263 | 0.400 |
Why?
|
Female | 91 | 2024 | 392544 | 0.400 |
Why?
|
Affect | 1 | 2020 | 1486 | 0.400 |
Why?
|
Male | 86 | 2024 | 360693 | 0.400 |
Why?
|
Quality of Life | 6 | 2021 | 13367 | 0.390 |
Why?
|
Radiotherapy, Conformal | 3 | 2016 | 548 | 0.370 |
Why?
|
Colorectal Neoplasms | 8 | 2022 | 6919 | 0.370 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1097 | 0.370 |
Why?
|
Vagina | 2 | 2022 | 841 | 0.350 |
Why?
|
Androgen Antagonists | 2 | 2009 | 1408 | 0.350 |
Why?
|
Sexual Behavior | 1 | 2020 | 2189 | 0.340 |
Why?
|
Disease-Free Survival | 9 | 2020 | 6819 | 0.340 |
Why?
|
Positron-Emission Tomography | 7 | 2022 | 6585 | 0.330 |
Why?
|
Embolization, Therapeutic | 1 | 2019 | 1419 | 0.330 |
Why?
|
Genital Neoplasms, Female | 1 | 2014 | 533 | 0.320 |
Why?
|
Fluorodeoxyglucose F18 | 6 | 2022 | 2024 | 0.320 |
Why?
|
Bone Marrow | 2 | 2017 | 2911 | 0.320 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2024 | 1784 | 0.320 |
Why?
|
Gastrectomy | 3 | 2024 | 671 | 0.300 |
Why?
|
Follow-Up Studies | 18 | 2024 | 39126 | 0.300 |
Why?
|
Collagen Diseases | 1 | 2007 | 39 | 0.290 |
Why?
|
Tumor Microenvironment | 6 | 2024 | 3873 | 0.290 |
Why?
|
Pancreatectomy | 4 | 2023 | 811 | 0.280 |
Why?
|
Adult | 49 | 2024 | 221119 | 0.280 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12474 | 0.270 |
Why?
|
Forecasting | 1 | 2016 | 2928 | 0.270 |
Why?
|
BCG Vaccine | 1 | 2008 | 369 | 0.260 |
Why?
|
Intraoperative Care | 3 | 2019 | 767 | 0.260 |
Why?
|
Neoplasm, Residual | 3 | 2021 | 1008 | 0.250 |
Why?
|
Neoplasm Invasiveness | 6 | 2021 | 3590 | 0.250 |
Why?
|
Antineoplastic Agents | 9 | 2020 | 13632 | 0.240 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2019 | 1655 | 0.240 |
Why?
|
Geriatric Assessment | 1 | 2012 | 1409 | 0.240 |
Why?
|
Treatment Outcome | 24 | 2024 | 64681 | 0.230 |
Why?
|
Fertility | 1 | 2009 | 768 | 0.230 |
Why?
|
Cystectomy | 1 | 2008 | 634 | 0.230 |
Why?
|
Prospective Studies | 16 | 2021 | 54435 | 0.220 |
Why?
|
Physicians | 1 | 2021 | 4584 | 0.220 |
Why?
|
Time Factors | 4 | 2021 | 39957 | 0.220 |
Why?
|
Prostatic Neoplasms | 4 | 2024 | 11101 | 0.220 |
Why?
|
Infertility, Female | 1 | 2009 | 761 | 0.210 |
Why?
|
Camptothecin | 3 | 2017 | 591 | 0.200 |
Why?
|
Organoplatinum Compounds | 2 | 2015 | 407 | 0.200 |
Why?
|
SEER Program | 2 | 2018 | 1453 | 0.200 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2017 | 880 | 0.200 |
Why?
|
Feasibility Studies | 3 | 2023 | 5250 | 0.200 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2008 | 782 | 0.200 |
Why?
|
Jaundice | 1 | 2022 | 93 | 0.190 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 224 | 0.190 |
Why?
|
Losartan | 2 | 2023 | 263 | 0.190 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2009 | 1520 | 0.190 |
Why?
|
Nerve Tissue | 1 | 2021 | 78 | 0.180 |
Why?
|
Lymph Nodes | 4 | 2022 | 3461 | 0.180 |
Why?
|
Pancreaticoduodenectomy | 3 | 2019 | 509 | 0.180 |
Why?
|
Mastectomy, Segmental | 6 | 2012 | 955 | 0.170 |
Why?
|
Prostate-Specific Antigen | 1 | 2009 | 2465 | 0.170 |
Why?
|
Breast Neoplasms | 7 | 2012 | 20982 | 0.170 |
Why?
|
Intestine, Small | 3 | 2013 | 1207 | 0.160 |
Why?
|
Vascular Diseases | 1 | 2007 | 1160 | 0.160 |
Why?
|
Colostomy | 1 | 2019 | 105 | 0.160 |
Why?
|
United States | 14 | 2023 | 72339 | 0.160 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 428 | 0.160 |
Why?
|
Patient Selection | 4 | 2012 | 4246 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2015 | 937 | 0.150 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2014 | 297 | 0.150 |
Why?
|
Pilot Projects | 3 | 2021 | 8642 | 0.150 |
Why?
|
Veterans | 2 | 2022 | 2654 | 0.150 |
Why?
|
Bilirubin | 1 | 2020 | 436 | 0.150 |
Why?
|
Thrombosis | 2 | 2023 | 2944 | 0.150 |
Why?
|
Disease Progression | 6 | 2022 | 13511 | 0.140 |
Why?
|
Neurosciences | 1 | 2022 | 369 | 0.140 |
Why?
|
Treatment Refusal | 1 | 2020 | 430 | 0.140 |
Why?
|
Serum Albumin | 1 | 2020 | 674 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 250 | 0.140 |
Why?
|
Consensus | 4 | 2024 | 3134 | 0.140 |
Why?
|
Hepatectomy | 1 | 2020 | 557 | 0.130 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 360 | 0.130 |
Why?
|
Radiopharmaceuticals | 4 | 2022 | 2683 | 0.130 |
Why?
|
Treatment Failure | 2 | 2019 | 2643 | 0.130 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1052 | 0.130 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2008 | 2223 | 0.130 |
Why?
|
Cholecystitis | 1 | 2017 | 180 | 0.130 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2018 | 173 | 0.130 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3354 | 0.130 |
Why?
|
Tumor Escape | 1 | 2019 | 371 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 456 | 0.130 |
Why?
|
Propensity Score | 2 | 2023 | 1916 | 0.130 |
Why?
|
Receptor, erbB-2 | 3 | 2018 | 2553 | 0.130 |
Why?
|
Peritoneal Neoplasms | 1 | 2022 | 710 | 0.120 |
Why?
|
Gallbladder | 1 | 2017 | 308 | 0.120 |
Why?
|
Hepatitis C Antibodies | 3 | 1999 | 147 | 0.120 |
Why?
|
Osteocalcin | 1 | 2015 | 274 | 0.120 |
Why?
|
Models, Statistical | 2 | 2020 | 5081 | 0.120 |
Why?
|
Gene Expression Profiling | 5 | 2024 | 9416 | 0.120 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13385 | 0.120 |
Why?
|
Gastrointestinal Diseases | 2 | 2014 | 1201 | 0.120 |
Why?
|
Autoantigens | 1 | 1998 | 888 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4851 | 0.110 |
Why?
|
Receptors, Estrogen | 3 | 2011 | 2208 | 0.110 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 1743 | 0.110 |
Why?
|
Carcinoembryonic Antigen | 2 | 2014 | 335 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 7 | 2022 | 36415 | 0.110 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12052 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2024 | 5300 | 0.110 |
Why?
|
Hepatitis C | 4 | 2000 | 1579 | 0.110 |
Why?
|
Faculty, Medical | 1 | 2021 | 1205 | 0.110 |
Why?
|
Analysis of Variance | 2 | 2013 | 6223 | 0.110 |
Why?
|
Hepacivirus | 4 | 2000 | 1330 | 0.100 |
Why?
|
Intraoperative Period | 1 | 2013 | 510 | 0.100 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1348 | 0.100 |
Why?
|
Endometrial Neoplasms | 1 | 2022 | 1366 | 0.100 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1723 | 0.100 |
Why?
|
Glutarates | 1 | 2014 | 243 | 0.100 |
Why?
|
Clinical Trials as Topic | 3 | 2022 | 8003 | 0.100 |
Why?
|
Sequence Analysis, DNA | 3 | 2000 | 4739 | 0.100 |
Why?
|
Decision Making | 2 | 2018 | 3931 | 0.100 |
Why?
|
Age Factors | 6 | 2023 | 18384 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2019 | 2054 | 0.090 |
Why?
|
Surgical Mesh | 1 | 2013 | 311 | 0.090 |
Why?
|
Macrocyclic Compounds | 1 | 2010 | 68 | 0.090 |
Why?
|
Gastroparesis | 2 | 2010 | 138 | 0.090 |
Why?
|
Hepatitis C Antigens | 2 | 1999 | 34 | 0.080 |
Why?
|
Medical Oncology | 1 | 2021 | 2320 | 0.080 |
Why?
|
Radiation Protection | 1 | 2013 | 426 | 0.080 |
Why?
|
Lymphatic Irradiation | 1 | 2010 | 115 | 0.080 |
Why?
|
Mutation | 7 | 2020 | 30002 | 0.080 |
Why?
|
Cohort Studies | 6 | 2020 | 41496 | 0.080 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5493 | 0.080 |
Why?
|
Receptors, Progesterone | 2 | 2011 | 1129 | 0.080 |
Why?
|
Ghrelin | 1 | 2010 | 251 | 0.080 |
Why?
|
Neoplasms | 3 | 2022 | 22140 | 0.080 |
Why?
|
CA-19-9 Antigen | 2 | 2022 | 106 | 0.080 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2009 | 107 | 0.080 |
Why?
|
Lymph Node Excision | 2 | 2015 | 1270 | 0.080 |
Why?
|
Standard of Care | 2 | 2022 | 550 | 0.070 |
Why?
|
Sex Factors | 1 | 2021 | 10553 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3634 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2022 | 2915 | 0.070 |
Why?
|
Postoperative Care | 1 | 2014 | 1468 | 0.070 |
Why?
|
Liver | 2 | 2020 | 7514 | 0.070 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1164 | 0.070 |
Why?
|
Comorbidity | 2 | 2012 | 10516 | 0.070 |
Why?
|
Cranial Irradiation | 1 | 2009 | 390 | 0.070 |
Why?
|
Immunotherapy | 2 | 2021 | 4642 | 0.070 |
Why?
|
Acute Disease | 1 | 2017 | 7226 | 0.070 |
Why?
|
Risk Factors | 7 | 2022 | 74239 | 0.070 |
Why?
|
Incidence | 4 | 2021 | 21365 | 0.060 |
Why?
|
Linear Models | 1 | 2015 | 5869 | 0.060 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2010 | 732 | 0.060 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4107 | 0.060 |
Why?
|
Colon | 1 | 2013 | 1791 | 0.060 |
Why?
|
Uterus | 1 | 2009 | 651 | 0.060 |
Why?
|
Young Adult | 9 | 2020 | 59221 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 20588 | 0.060 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2009 | 695 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5842 | 0.060 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2012 | 1084 | 0.060 |
Why?
|
Carcinoma | 1 | 2016 | 2330 | 0.060 |
Why?
|
Palliative Care | 1 | 2020 | 3599 | 0.060 |
Why?
|
Ovary | 1 | 2009 | 957 | 0.060 |
Why?
|
Biological Products | 1 | 2013 | 915 | 0.060 |
Why?
|
Abortion, Spontaneous | 1 | 2009 | 533 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2019 | 1746 | 0.060 |
Why?
|
Scleroderma, Systemic | 1 | 2007 | 345 | 0.060 |
Why?
|
Databases, Factual | 1 | 2019 | 7966 | 0.060 |
Why?
|
Diabetes Complications | 1 | 2010 | 1316 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2018 | 9025 | 0.050 |
Why?
|
Adenomatous Polyposis Coli Protein | 2 | 2014 | 181 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 86 | 0.050 |
Why?
|
DNA, Viral | 2 | 2000 | 2195 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
Jejunostomy | 1 | 2002 | 59 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2004 | 0.050 |
Why?
|
Quality Indicators, Health Care | 2 | 2022 | 1789 | 0.050 |
Why?
|
Contrast Media | 1 | 2015 | 5311 | 0.050 |
Why?
|
Kinetics | 1 | 2009 | 6312 | 0.050 |
Why?
|
Survival Analysis | 2 | 2019 | 10088 | 0.050 |
Why?
|
Postoperative Complications | 3 | 2020 | 15637 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 160 | 0.050 |
Why?
|
Physics | 1 | 2021 | 92 | 0.050 |
Why?
|
Nervous System Physiological Phenomena | 1 | 2022 | 114 | 0.050 |
Why?
|
Risk | 2 | 2011 | 9616 | 0.050 |
Why?
|
Diarrhea | 2 | 2022 | 1316 | 0.050 |
Why?
|
Sensitivity and Specificity | 4 | 2022 | 14675 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 127 | 0.050 |
Why?
|
Medicare | 1 | 2019 | 6773 | 0.050 |
Why?
|
Sequence Homology, Nucleic Acid | 2 | 1999 | 1053 | 0.050 |
Why?
|
Lamivudine | 1 | 2022 | 366 | 0.040 |
Why?
|
Recurrence | 2 | 2011 | 8457 | 0.040 |
Why?
|
Portal Vein | 1 | 2023 | 432 | 0.040 |
Why?
|
GTP Phosphohydrolases | 2 | 2014 | 517 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10203 | 0.040 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2004 | 617 | 0.040 |
Why?
|
Genes, MHC Class I | 1 | 2021 | 235 | 0.040 |
Why?
|
Societies, Medical | 2 | 2009 | 3923 | 0.040 |
Why?
|
Dermatoglyphics | 1 | 1999 | 20 | 0.040 |
Why?
|
Carbon | 1 | 2024 | 665 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2024 | 8530 | 0.040 |
Why?
|
Tissue Transplantation | 1 | 2000 | 128 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8663 | 0.040 |
Why?
|
Logistic Models | 1 | 2014 | 13249 | 0.040 |
Why?
|
Preoperative Period | 1 | 2022 | 551 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15308 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 782 | 0.040 |
Why?
|
Adolescent | 7 | 2023 | 88298 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 637 | 0.040 |
Why?
|
DNA, Recombinant | 1 | 1999 | 455 | 0.040 |
Why?
|
Body Mass Index | 1 | 2017 | 12952 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 3691 | 0.040 |
Why?
|
Viral Hepatitis Vaccines | 1 | 1999 | 72 | 0.040 |
Why?
|
Carboplatin | 2 | 2017 | 793 | 0.040 |
Why?
|
Snakes | 1 | 1998 | 27 | 0.040 |
Why?
|
Plants, Toxic | 1 | 1998 | 71 | 0.040 |
Why?
|
ras Proteins | 2 | 2014 | 1055 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2004 | 2219 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7400 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 702 | 0.040 |
Why?
|
Transplantation Immunology | 1 | 2000 | 537 | 0.040 |
Why?
|
Survivors | 1 | 2009 | 2369 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
Pan troglodytes | 1 | 1998 | 223 | 0.040 |
Why?
|
Zea mays | 1 | 1998 | 110 | 0.040 |
Why?
|
Species Specificity | 2 | 2000 | 2406 | 0.040 |
Why?
|
Vaccines, DNA | 1 | 1999 | 280 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 934 | 0.040 |
Why?
|
Protons | 1 | 2023 | 1111 | 0.040 |
Why?
|
Cell Communication | 1 | 2024 | 1651 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2022 | 928 | 0.040 |
Why?
|
RNA, Untranslated | 1 | 2000 | 453 | 0.040 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 312 | 0.030 |
Why?
|
Tacrolimus | 1 | 2000 | 736 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 307 | 0.030 |
Why?
|
Epirubicin | 1 | 2016 | 81 | 0.030 |
Why?
|
Enteral Nutrition | 1 | 2002 | 794 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 734 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1613 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1010 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 780 | 0.030 |
Why?
|
Cholelithiasis | 1 | 2017 | 407 | 0.030 |
Why?
|
Risk Assessment | 2 | 2022 | 24021 | 0.030 |
Why?
|
Advisory Committees | 2 | 2009 | 788 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 996 | 0.030 |
Why?
|
Publication Bias | 1 | 2015 | 160 | 0.030 |
Why?
|
Paclitaxel | 2 | 2017 | 1730 | 0.030 |
Why?
|
Radiometry | 1 | 2020 | 812 | 0.030 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2015 | 32 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3210 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 10218 | 0.030 |
Why?
|
Gait | 1 | 1999 | 810 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
Gene Amplification | 1 | 2018 | 1084 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2015 | 12159 | 0.030 |
Why?
|
Esophagectomy | 1 | 2017 | 469 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2015 | 1376 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2451 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3584 | 0.030 |
Why?
|
Functional Laterality | 1 | 1999 | 2257 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 270 | 0.030 |
Why?
|
Informed Consent | 2 | 2009 | 1008 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1589 | 0.030 |
Why?
|
Intestine, Large | 1 | 2012 | 69 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2709 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2000 | 1882 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4513 | 0.020 |
Why?
|
Endosonography | 1 | 2015 | 608 | 0.020 |
Why?
|
Genes, ras | 1 | 2014 | 654 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1985 | 0.020 |
Why?
|
Genotype | 2 | 2017 | 12985 | 0.020 |
Why?
|
Cisplatin | 1 | 2017 | 1652 | 0.020 |
Why?
|
Base Sequence | 2 | 1999 | 12404 | 0.020 |
Why?
|
Defecation | 1 | 2012 | 190 | 0.020 |
Why?
|
Laparoscopy | 1 | 2002 | 2035 | 0.020 |
Why?
|
Satiety Response | 1 | 2010 | 47 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3048 | 0.020 |
Why?
|
Massachusetts | 2 | 2013 | 8837 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 899 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 3770 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2016 | 1264 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 1999 | 17598 | 0.020 |
Why?
|
Stomach | 1 | 2013 | 697 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3499 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2194 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2009 | 26199 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7189 | 0.020 |
Why?
|
Appetite | 1 | 2010 | 247 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3688 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 16952 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 590 | 0.020 |
Why?
|
Vaccination | 1 | 1999 | 3369 | 0.020 |
Why?
|
Pregnancy | 1 | 2009 | 29893 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2014 | 7851 | 0.020 |
Why?
|
Vomiting | 1 | 2010 | 650 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7804 | 0.020 |
Why?
|
Viral Envelope Proteins | 2 | 1999 | 639 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11067 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4372 | 0.020 |
Why?
|
Thiotepa | 1 | 2004 | 66 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2022 | 9566 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 2864 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4574 | 0.010 |
Why?
|
Animals | 6 | 2022 | 168079 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2010 | 10756 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14610 | 0.010 |
Why?
|
Patient Readmission | 1 | 2017 | 3265 | 0.010 |
Why?
|
Melphalan | 1 | 2004 | 420 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 2 | 1999 | 1838 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4822 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20119 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4052 | 0.010 |
Why?
|
Cebidae | 1 | 2000 | 21 | 0.010 |
Why?
|
Intubation, Gastrointestinal | 1 | 2002 | 165 | 0.010 |
Why?
|
Signal Transduction | 1 | 2024 | 23416 | 0.010 |
Why?
|
Cercopithecidae | 1 | 2000 | 22 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3198 | 0.010 |
Why?
|
Polymerase Chain Reaction | 2 | 2000 | 6067 | 0.010 |
Why?
|
Mice, Inbred BALB C | 2 | 1999 | 6199 | 0.010 |
Why?
|
Heart Failure | 1 | 2004 | 11701 | 0.010 |
Why?
|
Viral Core Proteins | 1 | 1999 | 158 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 2000 | 1159 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1999 | 849 | 0.010 |
Why?
|
Cerebral Palsy | 1 | 2002 | 477 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 22174 | 0.010 |
Why?
|
Mouth Neoplasms | 1 | 2002 | 596 | 0.010 |
Why?
|
Pain | 1 | 2012 | 5072 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2010 | 12341 | 0.010 |
Why?
|
Intestinal Diseases | 1 | 2000 | 503 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2013 | 9187 | 0.010 |
Why?
|
Postoperative Period | 1 | 2000 | 1818 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2010 | 3417 | 0.010 |
Why?
|
Huntington Disease | 1 | 2002 | 1145 | 0.010 |
Why?
|
Probability | 1 | 2000 | 2478 | 0.010 |
Why?
|
Genetics, Population | 1 | 1999 | 935 | 0.010 |
Why?
|
Plasmids | 1 | 1999 | 2261 | 0.010 |
Why?
|
China | 1 | 1999 | 2374 | 0.010 |
Why?
|
Anorexia Nervosa | 1 | 2002 | 1361 | 0.010 |
Why?
|
Phylogeny | 1 | 2000 | 2809 | 0.010 |
Why?
|
HeLa Cells | 1 | 1999 | 3073 | 0.010 |
Why?
|
Gene Frequency | 1 | 1999 | 3603 | 0.010 |
Why?
|
Reoperation | 1 | 2002 | 4303 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2000 | 4822 | 0.010 |
Why?
|
Graft Survival | 1 | 2000 | 3843 | 0.010 |
Why?
|
Graft Rejection | 1 | 2000 | 4481 | 0.000 |
Why?
|
Rats | 1 | 2000 | 23704 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1999 | 18926 | 0.000 |
Why?
|
Cell Proliferation | 1 | 1999 | 10422 | 0.000 |
Why?
|
Mice | 2 | 1999 | 81326 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2000 | 18220 | 0.000 |
Why?
|
Child | 1 | 1999 | 80152 | 0.000 |
Why?
|